Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (531)	5/4/1998 3:20:00 PM
From: BulbaMan	Respond to of 2135

MAGN press release just out today on their angiogenesis inhibitor program. See link below. biz.yahoo.com

To: scaram(o)uche who wrote (531)	5/4/1998 3:27:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 2135

Thanks, and thanks also to Mike G who just posted, since I was pretty much just trading MAGN anyway (buying around 5.5 selling around 6.5) I will take my gains and put half the profit into NTII, based on shifting gears toward some speculative neuro. MAGN's press release smacks of hype, the timing anyway, and although it may run up some more, I had a thot of putting a stop loss in at 8 anyway, and since it did retrace to that point, what the heck, I'm out. I will let rgen run some more, perhaps with a stop loss around 3. Readers who like the neuro idea may want to check out NTII, but do your homework for godsake. Back to bed for me.